Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy

Cho, Han Joo; Kim, Kyoung Min; Kim, Hyoung Seok; Han, Ju; Kim, Chul Gu; Lee, Tae Gon; Kim, Jong Woo

doi:10.1016/j.ajo.2016.02.019

Cited by 66 publications

(61 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent reports have demonstrated IVR as noninferior to IVA in a short-term study 9 and in patients with PCV. 10 Although there was a trend toward greater visual improvement in the IVA group of the present study, no significant differences in the degree of improvement in BCVA, decrease in CFT, or mean number of injections were observed between the two treatment agents. To the best of our knowledge, the present report is the first to describe the evaluation of anti-VEGF agents by comparing time to retreatment and visual outcomes between IVR and IVA in patients with neovascular AMD.…”

Section: Discussioncontrasting

confidence: 62%

Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration

Inoue

Yamane

Sato

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 62%

Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration

Inoue

Yamane

Sato

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

“…Although direct comparisons cannot be made due to differences in maintenance phase regimens (fixed dosing or as needed), our results suggest that aflibercept is more effective than ranibizumab monotherapy. Cho et al [22] reported 1-year results of a study comparing aflibercept and ranibizumab monotherapy in PCV patients retrospectively. They reported that with regard to polyp resolution, aflibercept (39.5%) was more effective than ranibizumab (21.6%).…”

Section: Discussionmentioning

confidence: 99%

One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study

et al. 2017

View full text Add to dashboard Cite

Purpose: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. Methods: In this prospective, open-label, single-arm multicenter clinical trial, treatment-naïve PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. Results: Fifty eyes with PCV were included in the study. BCVA was maintained or improved in 97.6% of the patients. Mean logMAR BCVA at baseline was 0.33, and had improved to 0.12 logMAR 1 year after the initiation of aflibercept treatment (p < 0.001). Mean central foveal thickness decreased from 356 to 239 μm (p < 0.001). Complete regression of polypoidal lesions was seen in 72.5% after 1 year of treatment. Conclusions: One year of IVA resulted in stabilization of BCVA and anatomical improvement in Japanese PCV patients.

show abstract

“…In addition, when we analyzed specific anatomical lesions (e.g., SRF, PED), all parameters improved throughout the treatment. Cho et al [17] showed comparable results following use of either intravitreal ranibizumab or aflibercept treatment in 98 PCV patients. In their study, BCVA and CFT improved after 12 months of treatment, but the relative improvements did not differ between treatment groups.…”

Section: Discussionmentioning

confidence: 95%

“…These results suggest that aflibercept monotherapy might be a compatible and promising treatment for PCV. To date, only one study has compared intravitreal ranibizumab and af libercept treatments for PCV [17]. This work showed a significant improvement in visual acuity after 12 months of treatment; however, no difference in acuity was found between the therapeutic agents.…”

Section: Introductionmentioning

confidence: 83%

Comparing Ranibizumab and Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy

Song

Cho

Kim

et al. 2018

J Retin

View full text Add to dashboard Cite

Purpose:To compare the clinical efficacy of intravitreal ranibizumab and aflibercept in treatment-naïve patients with polypoidal choroidal vasculopathy (PCV). Methods: We retrospectively analyzed the medical records of 82 eyes with treatment-naïve PCV who were treated with ranibizumab or aflibercept and followed for at least six months. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) as measured by optical coherence tomography (OCT), and polyp size in indocyanine green angiography (ICGA) were used for evaluation. The primary endpoint was change at 12 months relative to baseline with respect to BCVA and CFT. Secondary endpoints were anatomical changes in OCT and ICGA findings from baseline. Results: Data from 46 eyes were considered for the primary endpoint. Twenty-five and 21 eyes received ranibizumab and aflibercept, respectively. Statistically significant improvements in BCVA and CFT compared with baseline were noted in both groups. Of 82 eyes assessed for secondary endpoints, 52 and 30 received ranibizumab and aflibercept, respectively. The subretinal fluid , pigment epithelial detachment , and subfoveal thickness decreased significantly throughout the follow-up in each group. Polyp regression was found in 37.5% and 32.4% of the ranibizumab-and aflibercept-treated groups, respectively. However, there was no significant difference in the treatment results between the drugs. Conclusions: In a comparison of the clinical efficacy of intravitreal ranibizumab and that of aflibercept in patients with PCV, the treatment groups showed similar clinical results in terms of functional and anatomical outcomes after 12 months.

show abstract

Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy

Cited by 66 publications

References 23 publications

Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration

Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration

One-Year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO Study

Comparing Ranibizumab and Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy

Contact Info

Product

Resources

About